The current article provides the latest information on recent approvals, advancements, and improvements in the anemia and other red cell disorders from the last six months. Oral glutamine for sickle cell disease In July of 2017, the US FDA approved an L-glutamine formulation for reducing vaso-occlusive complications in individuals with sickle cell disease (SCD). The approval was based on a trial (as yet unpublished) in which 230 individuals with SCD who had frequent pain episodes were treated with daily oral glutamine or placebo for a year.
Compared with placebo, glutamine reduced the frequency of pain episodes, acute chest syndrome, and hospitalization. Low-dose ferrous sulfate for iron deficiency anemia For infants and children with iron deficiency anemia, standard oral iron dosing is 3 to 6 mg/kg elemental iron per day , but the optimal dose and preparation have not been established.…
